Some rectal cancer patients might be spared surgery and the lifelong need for a colostomy bag if they undergo MRI screening, a new study finds. The scans might accurately predict which patients have a ...

Please provide your email address to receive an email when new articles are posted on . MRI can help determine which individuals with rectal cancer may not need surgery following neoadjuvant therapy.

An MRI exam can identify residual disease and predict rectal patient outcomes, making it a useful resource to identify patients suitable for a watch-and-wait protocol, according to a study published ...

Findings can save some lower-risk patients surgery after chemo, radiation. (HealthDay News) — Restaging magnetic resonance imaging (MRI) can predict organ preservation and survival with rectal cancer, ...

The availability of tools that can accurately measure response is critical for the selection of patients with rectal cancer who can be offered organ-saving treatment After preoperative ...

MRI can predict the risk of rectal cancer reccurring or spreading for patients who have undergone chemotherapy and radiation, new research indicates. Magnetic resonance imaging (MRI) can spare many ...

3T MRI can accurately stage, and help surgeons plan sphincter-sparing surgery in patients with rectal cancer, according to a recent study. 3T MRI can accurately stage, and help surgeons plan sphincter ...

Wieder et al. have demonstrated that prediction of the circumferential resection margin by MRI performed before neoadjuvant therapy and total mesorectal excision (TME) is a prognostic factor in ...

Magnetic resonance imaging (MRI) can spare many patients with rectal cancer from invasive surgery that can carry lifelong side effects, new research indicates. The findings, from UVA Cancer Center's ...

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer In a prospective cohort study, 111 patients who had rectal cancer treated by neoadjuvant therapy ...

CHICAGO -- Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to ...

“No one wants to get surgery if they can avoid it. Now we have a powerful tool to help patients and their doctors predict who would benefit from surgery after initial chemotherapy and radiation and ...